Trial Profile
The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary) ; Nitrogen
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- Sponsors Ikaria Holdings; Mallinckrodt Inc.
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 21 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.
- 25 May 2014 New trial record